tirzepatide weight loss clinical trials Reduction of prevalence of patients meeting the criteria for metabolic syndrome with tirzepatide: a post hoc analysis from the SURPASS Trial Program | Cardiovascular Diabetology Tirzepatide for Weight Loss |

Stimulates pulsatile growth-hormone release without significant effect on ACTH, cortisol, or prolactin in published models the basis for its selective GHRP classification

Cost considerations may influence treatment decisions and adherence for some individuals, particularly those on fixed incomes or with limited financial resources

Body aches are not among the most frequently reported side effects of tirzepatide, but some patients do experience mild musculoskeletal discomfort during their first 2 to 4 weeks of treatment

Patients with superficial basal cell carcinoma or intraepidermal carcinoma (squamous cell carcinoma in situ) may be safely managed with cryotherapy or topical treatments, i.e